441 related articles for article (PubMed ID: 33332001)
1. Neuromolecular Mechanisms of Cannabis Action.
Adel Y; Alexander SPH
Adv Exp Med Biol; 2021; 1264():15-28. PubMed ID: 33332001
[TBL] [Abstract][Full Text] [Related]
2. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin.
Pertwee RG
Br J Pharmacol; 2008 Jan; 153(2):199-215. PubMed ID: 17828291
[TBL] [Abstract][Full Text] [Related]
3. Examining the role of cannabinoids on osteoporosis: a review.
Clouse G; Penman S; Hadjiargyrou M; Komatsu DE; Thanos PK
Arch Osteoporos; 2022 Nov; 17(1):146. PubMed ID: 36401719
[TBL] [Abstract][Full Text] [Related]
4. Constituents of Cannabis Sativa.
Rock EM; Parker LA
Adv Exp Med Biol; 2021; 1264():1-13. PubMed ID: 33332000
[TBL] [Abstract][Full Text] [Related]
5. Psychomotor performance in relation to acute oral administration of Delta9-tetrahydrocannabinol and standardized cannabis extract in healthy human subjects.
Roser P; Gallinat J; Weinberg G; Juckel G; Gorynia I; Stadelmann AM
Eur Arch Psychiatry Clin Neurosci; 2009 Aug; 259(5):284-92. PubMed ID: 19224107
[TBL] [Abstract][Full Text] [Related]
6. The loss of NMDAR-dependent LTD following cannabinoid self-administration is restored by positive allosteric modulation of CB1 receptors.
Neuhofer D; Spencer SM; Chioma VC; Beloate LN; Schwartz D; Kalivas PW
Addict Biol; 2020 Nov; 25(6):e12843. PubMed ID: 31733097
[TBL] [Abstract][Full Text] [Related]
7. A randomised controlled trial of vaporised Δ
Solowij N; Broyd S; Greenwood LM; van Hell H; Martelozzo D; Rueb K; Todd J; Liu Z; Galettis P; Martin J; Murray R; Jones A; Michie PT; Croft R
Eur Arch Psychiatry Clin Neurosci; 2019 Feb; 269(1):17-35. PubMed ID: 30661105
[TBL] [Abstract][Full Text] [Related]
8. Effects of delta-9-tetrahydrocannabinol, 11-hydroxy-delta-9-tetrahydrocannabinol and cannabidiol on neuromuscular transmission in the frog.
Turkanis SA; Karler R
Neuropharmacology; 1986 Nov; 25(11):1273-8. PubMed ID: 3025765
[TBL] [Abstract][Full Text] [Related]
9. Antidepressant-like effect of delta9-tetrahydrocannabinol and other cannabinoids isolated from Cannabis sativa L.
El-Alfy AT; Ivey K; Robinson K; Ahmed S; Radwan M; Slade D; Khan I; ElSohly M; Ross S
Pharmacol Biochem Behav; 2010 Jun; 95(4):434-42. PubMed ID: 20332000
[TBL] [Abstract][Full Text] [Related]
10. Neuropharmacological Effects of the Main Phytocannabinoids: A Narrative Review.
Dos Santos RG; Hallak JEC; Crippa JAS
Adv Exp Med Biol; 2021; 1264():29-45. PubMed ID: 33332002
[TBL] [Abstract][Full Text] [Related]
11. Cannabinoids, hippocampal excitability and efficacy for the treatment of epilepsy.
Yao I; Stein ES; Maggio N
Pharmacol Ther; 2019 Oct; 202():32-39. PubMed ID: 31176695
[TBL] [Abstract][Full Text] [Related]
12. ¹H NMR and HPLC/DAD for Cannabis sativa L. chemotype distinction, extract profiling and specification.
Peschel W; Politi M
Talanta; 2015 Aug; 140():150-165. PubMed ID: 26048837
[TBL] [Abstract][Full Text] [Related]
13. Changes in neurotransmitter release at a neuromuscular junction of the lobster caused by cannabinoids.
Turkanis SA; Karler R
Neuropharmacology; 1988 Jul; 27(7):737-42. PubMed ID: 2901683
[TBL] [Abstract][Full Text] [Related]
14. Complex pharmacology of natural cannabinoids: evidence for partial agonist activity of delta9-tetrahydrocannabinol and antagonist activity of cannabidiol on rat brain cannabinoid receptors.
Petitet F; Jeantaud B; Reibaud M; Imperato A; Dubroeucq MC
Life Sci; 1998; 63(1):PL1-6. PubMed ID: 9667767
[TBL] [Abstract][Full Text] [Related]
15. Source of cannabinoids: what is available, what is used, and where does it come from?
Specchio N; Pietrafusa N; Cross HJ
Epileptic Disord; 2020 Jan; 22(S1):1-9. PubMed ID: 31941643
[TBL] [Abstract][Full Text] [Related]
16. Cytotoxic Effects of Cannabinoids on Human HT-29 Colorectal Adenocarcinoma Cells: Different Mechanisms of THC, CBD, and CB83.
Cerretani D; Collodel G; Brizzi A; Fiaschi AI; Menchiari A; Moretti E; Moltoni L; Micheli L
Int J Mol Sci; 2020 Aug; 21(15):. PubMed ID: 32752303
[TBL] [Abstract][Full Text] [Related]
17. Pharmacology of cannabinoids in the treatment of epilepsy.
Gaston TE; Friedman D
Epilepsy Behav; 2017 May; 70(Pt B):313-318. PubMed ID: 28087250
[TBL] [Abstract][Full Text] [Related]
18. Molecular Mechanism and Cannabinoid Pharmacology.
Schurman LD; Lu D; Kendall DA; Howlett AC; Lichtman AH
Handb Exp Pharmacol; 2020; 258():323-353. PubMed ID: 32236882
[TBL] [Abstract][Full Text] [Related]
19. Phytocannabinoid Pharmacology: Medicinal Properties of
Sampson PB
J Nat Prod; 2021 Jan; 84(1):142-160. PubMed ID: 33356248
[TBL] [Abstract][Full Text] [Related]
20. The anti-inflammatory effects of cannabidiol and cannabigerol alone, and in combination.
Robaina Cabrera CL; Keir-Rudman S; Horniman N; Clarkson N; Page C
Pulm Pharmacol Ther; 2021 Aug; 69():102047. PubMed ID: 34082108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
